How many ai startups are there?

Why there’s no single “correct” number of AI startups

“How many AI startups are there?” sounds like a clean counting question, but it’s not—because the label AI startup is fuzzy and the data sources don’t agree. Two analysts can use reputable databases and produce very different totals, both “right” by their definitions.

Here are the main reasons:

• Definition drift: Some sources count any company that mentions “AI/ML” in marketing. Others require AI to be core to the product (e.g., model performance is the value, not just a feature).
• Startup vs. company: Is a 12-year-old venture-backed firm still a startup? What about a bootstrapped clinic software vendor with 200 employees?
• Geography and language: Many datasets skew toward US/EU and English-language coverage.
• Duplicates and rebrands: The same company can appear multiple times across sources, or disappear after acquisition.
• Stealth and “internal AI”: A lot of clinically relevant AI is built inside incumbents (EHR vendors, imaging OEMs, payers) and never shows up as a “startup.”

So the useful goal isn’t a single global number. The useful goal is: how many relevant AI startups exist in your specific medtech niche and buying context (e.g., ICU deterioration prediction for adult inpatient settings in the US, sold to hospitals, requiring reimbursement or budget justification).

A practical way to estimate the number (and make it actionable)

Instead of chasing a universal count, build a defensible estimate using a clear filter. This is how investors and corporate strategy teams do it when they need an answer they can act on.

Step 1: Define “AI startup” for your purpose

Pick one of these definitions and stick to it:

• Broad: Any early-stage company that markets AI/ML as part of its product.
• Product-core AI: The product’s measurable value depends on an ML model (performance, sensitivity/specificity, time-to-diagnosis, automation rate, etc.).
• Regulated clinical AI: The product is intended for diagnosis, treatment, mitigation, or prevention and therefore may require FDA clearance/approval (or equivalent).

For medtech, the third definition is often the most useful because it aligns with real go-to-market constraints: clinical validation, regulatory pathway, hospital procurement, and reimbursement.

Step 2: Narrow to a segment you can actually count

“Medtech AI” is still huge. Narrow by:

• Clinical domain: radiology, cardiology, pathology, dermatology, ICU, oncology, orthopedics, etc.
• Modality: imaging, waveform (ECG/EEG), EHR text, wearables, lab data, multimodal.
• Care setting: inpatient hospital, outpatient clinic, home monitoring, EMS.
• Buyer: hospital department, IT, value-based care org, payer, employer.

This turns the question into something like: “How many startups sell FDA-cleared AI for radiology workflow in the US?” That’s countable.

Step 3: Use multiple sources and reconcile

No single database is complete. Use at least two categories of sources:

• Company databases (good for breadth): startup directories, funding databases, accelerator cohorts.
• Regulatory and clinical signals (good for relevance): FDA device listings, published validation studies, hospital deployments, IRB-approved trials.

Then reconcile by deduping and applying your definition filter (e.g., exclude “AI-enabled scheduling” if you only care about regulated clinical decision support).

Medtech-specific reality: “AI startup” counts depend on FDA pathway and claims

In medtech, the number of “AI startups” that matter to a hospital buyer is usually far smaller than the number of “AI startups” that exist in general. The gating factor is claims—what you say your product does.

Regulatory pathways shape who counts as a competitor

If your product makes clinical claims, you may need an FDA pathway such as:

• 510(k): You show “substantial equivalence” to a predicate device. Common when similar products already exist.
• De Novo: For novel, lower-to-moderate risk devices without a predicate. Often used when you’re creating a new category.
• PMA: For higher-risk devices with more stringent evidence requirements.

Two startups can both say “AI for sepsis,” but if one is marketing as a non-device “operational analytics” tool and the other is pursuing a regulated indication, they’re in different competitive arenas. Your “how many are there?” should match your intended claims and pathway.

Reimbursement and procurement shrink the field further

Even among regulated products, the number that can scale is constrained by:

• Reimbursement: Is there a CPT code (or another payment mechanism) that supports adoption? If not, hospitals may require a strong ROI case or budget line item.
• Hospital procurement: Security review, integration (EHR/PACS), vendor onboarding, and contracting can take months. Many “startups” never clear this hurdle.
• Clinical evidence: Peer-reviewed studies, prospective validation, and sometimes IRB-approved evaluations matter—especially if outcomes claims are implied.

So a practical competitor count for medtech AI is often: companies with credible evidence + deployable integration + a plausible payment story, not just “companies that say AI.”

How to answer the question credibly in a pitch deck or market memo

If you need to put a number in front of investors, advisors, or a hospital champion, don’t present a single global count. Present a layered count with definitions.

Use a structure like this:

1. Universe (broad): “AI startups” across all industries (varies widely by definition and dataset).
2. Medtech AI (narrower): Companies applying AI to clinical workflows/devices (still varies).
3. Your niche (actionable): Companies addressing your specific indication, modality, setting, and buyer.
4. True alternatives (most actionable): What the buyer would do instead (incumbent workflow, manual process, internal model, or a non-AI device).

This approach avoids the trap of arguing about a global number and instead demonstrates that you understand the competitive landscape that actually affects adoption.

What to do next

• Write your counting definition in one sentence (e.g., “venture-backed companies selling regulated clinical AI to US hospitals”).
• Build a niche competitor table with 20–50 entries max: company, indication, modality, FDA status (if applicable), evidence type, integration surface (EHR/PACS), buyer, and pricing model.
• Map regulatory and payment constraints for your product: likely FDA pathway (510(k), De Novo, PMA), and whether reimbursement depends on CPT codes or hospital budget/ROI.
• Pressure-test your market narrative by comparing “AI competitors” vs. “status quo alternatives” (what clinicians do today).
• Get a fast external critique of your positioning and competitor set before you lock your deck.